These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25185192)

  • 1. ODM-201 is safe and active in metastatic castration-resistant prostate cancer.
    Cancer Discov; 2014 Sep; 4(9):OF10. PubMed ID: 25185192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Bjartell A
    Eur Urol; 2015 Feb; 67(2):348-9. PubMed ID: 25760250
    [No Abstract]   [Full Text] [Related]  

  • 4. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
    Fizazi K; Albiges L; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2015; 15(9):1007-17. PubMed ID: 26313416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will new AR inhibitors reshape the prostate cancer landscape?
    Tombal B
    Lancet Oncol; 2014 Aug; 15(9):912-3. PubMed ID: 24974052
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer: Phasing in new treatment.
    Stone L
    Nat Rev Urol; 2014 Aug; 11(8):423. PubMed ID: 25023597
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
    Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
    Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.
    Peltola KJ; Bono P; Jones RH; Vjaters E; Nykänen P; Vuorela A; Oksala R; Pohjanjousi P; Mustonen MVJ; Fizazi K; Massard C
    Eur Urol Focus; 2020 Jan; 6(1):63-70. PubMed ID: 30194031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.
    Massard C; Penttinen HM; Vjaters E; Bono P; Lietuvietis V; Tammela TL; Vuorela A; Nykänen P; Pohjanjousi P; Snapir A; Fizazi K
    Eur Urol; 2016 May; 69(5):834-40. PubMed ID: 26463318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
    Oksala R; Moilanen A; Riikonen R; Rummakko P; Karjalainen A; Passiniemi M; Wohlfahrt G; Taavitsainen P; Malmström C; Ramela M; Metsänkylä HM; Huhtaniemi R; Kallio PJ; Mustonen MV
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105115. PubMed ID: 29438723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
    Fizazi K; Massard C; Bono P; Kataja V; James N; Tammela TL; Joensuu H; Aspegren J; Mustonen M
    Eur Urol Focus; 2017 Dec; 3(6):606-614. PubMed ID: 28753849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment.
    Zhou M; Zheng H; Li Y; Huang H; Min X; Dai S; Zhou W; Chen Z; Xu G; Chen Y
    Aging (Albany NY); 2021 Feb; 13(5):6982-6998. PubMed ID: 33621955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
    Zhang F; Lu YP
    Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
    Fizazi K; Bernard-Tessier A; Roubaud G; Utriainen T; Barthélémy P; Fléchon A; van der Voet J; Gravis G; Ratta R; Jones R; Parikh O; Tanner M; Antonarakis ES; Baldini C; Peters N; Garratt C; Ikonen T; Pohjanjousi P; Joensuu H; Cook N
    NEJM Evid; 2024 Jan; 3(1):EVIDoa2300171. PubMed ID: 38320513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
    Dellis A; Papatsoris AG
    Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-metastatic castration-resistant prostate cancer: current status and future directions.
    Gupta R; Sheng IY; Barata PC; Garcia JA
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):513-522. PubMed ID: 32508166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
    Hu YH; Guo JC; Zhang M
    Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.